NCT00477542View on ClinicalTrials.gov

A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Hematologic Malignancies
Interventions
DRUG

clofarabine

"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70"

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Indiana University School of Medicine

OTHER

NCT00477542 - A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT | Biotech Hunter | Biotech Hunter